Petkovsek DS, et al. - Via this retrospective chart analysis, researchers assessed 3-year clinical outcomes of patients who received eplerenone for the treatment of chronic central serous chorioretinopathy (CSCR). At eplerenone initiation, baseline best-corrected visual acuity, as well as anatomical measurements associated with the degree of subretinal fluid (SRF), were obtained. At the closest date to 12, 24 and 36 months, follow-up data were gathered. They collected data at 1-year, 2-year, and 3-year follow-up visits, for 100 eyes of 83 patients, 49 eyes, and for 33 eyes, respectively. The observed rate of complete SRF resolution was 31%, 28% and 33%, respectively. In patients treated with eplerenone for chronic CSCR, the occurrence of anatomical improvement was evident primarily within the first year of treatment.